feed,title,long_url,short_url
Benzinga,BeiGene's Zanubrutinib Fails To Meet Efficacy Endpoints In Mid-Stage COVID-19 Study,https://benzinga.com/general/biotech/21/04/20536111/beigenes-zanubrutinib-fails-to-meet-efficacy-endpoints-in-mid-stage-covid-19-study,https://j.mp/3mwdsvt
Benzinga,Merck's Keytruda Shows Better Disease-Free Survival As Adjuvant Therapy In Kidney Cancer,https://benzinga.com/general/biotech/21/04/20536007/mercks-keytruda-shows-better-disease-free-survival-as-adjuvant-therapy-in-kidney-cancer,https://j.mp/2Q6T8oe
